NKGen Biotech, Inc. Common Stock
NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease… Read more
NKGen Biotech, Inc. Common Stock (NKGN) - Total Liabilities
Latest total liabilities as of December 2025: $66.17 Million USD
Based on the latest financial reports, NKGen Biotech, Inc. Common Stock (NKGN) has total liabilities worth $66.17 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
NKGen Biotech, Inc. Common Stock - Total Liabilities Trend (2021–2023)
This chart illustrates how NKGen Biotech, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
NKGen Biotech, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of NKGen Biotech, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Boldt S.A
BA:BOLT
|
Argentina | AR$54.72 Billion |
|
Mytrex Health Technologies, Inc.
TWO:4431
|
Taiwan | NT$544.57 Million |
|
Origin Agritech Ltd
NASDAQ:SEED
|
USA | $151.71 Million |
|
Odonate Therapeutics
PINK:ODTC
|
USA | $2.88 Million |
|
Keystone Reit Ltd
TA:KSTN
|
Israel | ILA1.91 Billion |
|
Julong Holding Limited Class A Ordinary Shares
NASDAQ:JLHL
|
USA | $23.51 Million |
Liability Composition Analysis (2021–2023)
This chart breaks down NKGen Biotech, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 4.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how NKGen Biotech, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for NKGen Biotech, Inc. Common Stock (2021–2023)
The table below shows the annual total liabilities of NKGen Biotech, Inc. Common Stock from 2021 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $75.17 Million | +409.07% |
| 2022-12-31 | $14.77 Million | -73.69% |
| 2021-12-31 | $56.12 Million | -- |